487 related articles for article (PubMed ID: 20648928)
21. Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction.
Drozd MD; Tkaczyszyn M; Kasztura M; Węgrzynowska-Teodorczyk K; Flinta I; Banasiak W; Ponikowski P; Jankowska EA
Cardiol J; 2024; 31(2):300-308. PubMed ID: 37853824
[TBL] [Abstract][Full Text] [Related]
22. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
[TBL] [Abstract][Full Text] [Related]
23. One-Bag 8-Step Ferric Carboxymaltose Desensitization Protocol for Patients with a History of Hypersensitivity Reactions to Iron Preparations.
Özden Ş; Tepetam FM; Atik Ö
Int Arch Allergy Immunol; 2024; 185(5):449-455. PubMed ID: 38272014
[TBL] [Abstract][Full Text] [Related]
24. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.
Frazier R; Hodakowski A; Cai X; Lee J; Zakarija A; Stein B; David V; Wolf M; Isakova T; Mehta R
Bone; 2020 Dec; 141():115559. PubMed ID: 32730929
[TBL] [Abstract][Full Text] [Related]
25. Administration of intravenous iron through a home-based infusion strategy is safe and has high patient acceptance.
Liu D; Atienza E; Santamaria L; Sinnappu R; Garg M
Intern Med J; 2024 Jan; 54(1):104-107. PubMed ID: 36938780
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of ferric carboxymaltose on haemoglobin response among older patients with gastrointestinal bleeding: a randomised clinical trial.
Richard N; Arab-Hocine N; Vannier M; Leblanc-Boubchir R; Pelaquier A; Boruchowicz A; Musikas M; Amil M; Fumery M; Nahon S; Arotcarena R; Gelsi E; Maurin A; Hébuterne X; Savoye G
Age Ageing; 2024 May; 53(5):. PubMed ID: 38706390
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data.
Moore RA; Gaskell H; Rose P; Allan J
BMC Blood Disord; 2011 Sep; 11():4. PubMed ID: 21942989
[TBL] [Abstract][Full Text] [Related]
28. Methodology and Baseline Data of a Comparative Exploratory Double-Blinded Randomized Study of Intravenous Iron on Fibroblast Growth Factor 23 and Phosphate in Chronic Kidney Disease.
Kassianides X; Bhandari S
Kidney Blood Press Res; 2023; 48(1):151-164. PubMed ID: 37015198
[TBL] [Abstract][Full Text] [Related]
29. Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial.
Pasricha SR; Mwangi MN; Moya E; Ataide R; Mzembe G; Harding R; Zinenani T; Larson LM; Demir AY; Nkhono W; Chinkhumba J; Simpson JA; Clucas D; Stones W; Braat S; Phiri KS
Lancet; 2023 May; 401(10388):1595-1609. PubMed ID: 37088092
[TBL] [Abstract][Full Text] [Related]
30. A Randomised Controlled Trial to Compare Injection Ferric Carboxymaltose and Oral Iron in Treating Iron Deficiency Anemia During Pregnancy.
Chawla S; Singh A; Jhamb D; Anupama CH
J Obstet Gynaecol India; 2022 Dec; 72(6):492-496. PubMed ID: 36506904
[TBL] [Abstract][Full Text] [Related]
31. Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study.
Wahid M; Islam S; Sepehrvand N; Dover DC; McAlister FA; Kaul P; Ezekowitz JA
Circ Heart Fail; 2024 Apr; 17(4):e011351. PubMed ID: 38572652
[TBL] [Abstract][Full Text] [Related]
32. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.
Kunka RL; Hussey EK; Shaw S; Warner P; Aubert B; Richard I; Fowler PA; Pakes GE
Cephalalgia; 1997 Jun; 17(4):532-40. PubMed ID: 9209775
[TBL] [Abstract][Full Text] [Related]
33. Effect of Ferric Carboxymaltose Versus Low-Dose Intravenous Iron Therapy and Iron Sucrose on the Total Cost of Care in Patients with Iron Deficiency Anemia: A US Claims Database Analysis.
Kwong WJ; Wang K; Wang P; Boccia R
Drugs Real World Outcomes; 2024 Mar; ():. PubMed ID: 38502304
[TBL] [Abstract][Full Text] [Related]
34. Intravenous iron administration before cardiac surgery reduces red blood cell transfusion in patients without anaemia.
Friedman T; Dann EJ; Bitton-Worms K; Makhoul M; Glam R; Weis A; Tam DY; Bolotin G
Br J Anaesth; 2023 Dec; 131(6):981-988. PubMed ID: 37838604
[TBL] [Abstract][Full Text] [Related]
35. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients.
Zanen AL; Adriaansen HJ; van Bommel EF; Posthuma R; Th de Jong GM
Nephrol Dial Transplant; 1996 May; 11(5):820-4. PubMed ID: 8671901
[TBL] [Abstract][Full Text] [Related]
36. Comparison of efficacy, tolerability, and cost of iron polymaltose complex with ferrous sulphate in the treatment of iron deficiency anemia in pregnant women.
Saha L; Pandhi P; Gopalan S; Malhotra S; Saha PK
MedGenMed; 2007 Jan; 9(1):1. PubMed ID: 17435611
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
Ponikowski P; Mentz RJ; Hernandez AF; Butler J; Khan MS; van Veldhuisen DJ; Roubert B; Blackman N; Friede T; Jankowska EA; Anker SD
Eur Heart J; 2023 Dec; 44(48):5077-5091. PubMed ID: 37632415
[TBL] [Abstract][Full Text] [Related]
38. Retrospective Study Comparing Treatment Outcomes in Obstetric Patients With Iron Deficiency Anemia Treated With and Without Intravenous Ferric Carboxymaltose.
Li M; Wright A; Rahim AM; Tan KH; Tagore S
Cureus; 2024 Mar; 16(3):e55713. PubMed ID: 38586790
[TBL] [Abstract][Full Text] [Related]
39. Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials.
Fukumoto S; Murata T; Osuga Y; Pollock RF
Adv Ther; 2023 Nov; 40(11):4877-4888. PubMed ID: 37702931
[TBL] [Abstract][Full Text] [Related]
40. The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses.
Yang Y; Yu L; Sheng Z; Lin H; Weng Z; Song W; Cao B; Zhao Y; Gao Y; Ni S; Wang H; Ma T; Huang L; Sun C; Li J
Front Pharmacol; 2024; 15():1327008. PubMed ID: 38741586
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
